Evidence map›Paper›PMID 26156733›Full record

Trial reportThe American journal of clinical nutrition2015

Insulin secretion and sensitivity in healthy adults with low vitamin D are not affected by high-dose ergocalciferol administration: a randomized controlled trial.

Deborah M Mitchell, Benjamin Z Leder, Enrico Cagliero, Natalia Mendoza, Maria P Henao, Douglas L Hayden, Joel S Finkelstein, Sherri-Ann M Burnett-Bowie

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The American journal of clinical nutrition, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 4 pooled it
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 4 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Content of Vitamin DMetabolites · 2026
    Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Deborah M MitchellEndocrine Unit, Pediatric Endocrine Unit, dmmitchell@mgh.harvard.edu.ORCID http://orcid.org/0000-0003-0364-9107
Benjamin Z LederEndocrine Unit.
Enrico CaglieroDiabetes Center, and.
Natalia MendozaEndocrine Unit.
Maria P HenaoEndocrine Unit.
Douglas L HaydenBiostatistics Center, Massachusetts General Hospital, Boston, MA.
Joel S FinkelsteinEndocrine Unit.
Sherri-Ann M Burnett-BowieEndocrine Unit.ORCID http://orcid.org/0000-0002-0064-096X
Endocrine Society · USDiabetes Australia · AUMassachusetts General Hospital · US

Funding

Harvard Clinical and Translational Science Center (UL1)UL1TR000170 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2012 to 2013
$31.4M
Dietary and hormonal regulation of FGF-23 in humansK23DK073356 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI BURNETT-BOWIE, SHERRI-ANN M · 2006 to 2010
$737k
NCATS NIH HHS 8UL1TR000170-05NCATS NIH HHS UL1 TR000170NIDDK NIH HHS K23DK073356
6 · The paper itself

Abstract

backgroundEpidemiologic data suggest that low serum 25-hydroxyvitamin D [25(OH)D] increases insulin resistance and the risk of type 2 diabetes. Few interventional trials have assessed the effect of vitamin D on insulin metabolism, and published results are discordant.

objectiveThe goal of this study was to perform a detailed assessment of the effect of ergocalciferol administration on glucose and insulin metabolism in healthy people with low total 25(OH)D(total).

designThis was a 12-wk, double-blinded, randomized controlled trial. We enrolled 90 healthy volunteers aged 18-45 y with serum 25(OH)D ≤20 ng/mL (by immunoassay) and administered 50,000 IU ergocalciferol/wk or placebo for 12 wk. Primary endpoints were change in first-phase insulin response and insulin sensitivity as measured by intravenous glucose tolerance test. Secondary endpoints included change in homeostasis model assessment of insulin resistance; fasting glucose, insulin, and lipids; body mass index (BMI); and blood pressure.

resultsOn-study 25(OH)D(total) was assessed by liquid chromatography-tandem mass spectrometry. In the treated group, 25(OH)D(total) rose from 18 ± 7 to 43 ± 12 ng/mL (P < 0.001) with no change in the placebo group. Despite this increase, at 12 wk, there were no between-group differences in either insulin response or insulin sensitivity; nor were there differences in any measured secondary endpoints. There was no evidence of effect modification by sex, race, glucose tolerance status, baseline 25(OH)D(total), or BMI.

conclusionIn healthy persons with low 25(OH)D(total), ergocalciferol administration for 12 wk normalizes 25(OH)D(total) but does not improve insulin secretion, insulin sensitivity, or other markers of metabolic health.

Indexed as

Dietary SupplementsInsulin Resistance25-Hydroxyvitamin D 2AdultBiomarkersBostonCalcifediolCohort StudiesDiabetes Mellitus, Type 2Double-Blind MethodErgocalciferolsFemaleHumansInsulinInsulin SecretionLongitudinal Studies25-Hydroxyvitamin D 2BiomarkersCalcifediolErgocalciferolsInsulindiabetesergocalciferolglucoseinsulininsulin resistancevitamin D

Identifiers

PMID26156733
PMCPMC4515870
OpenAlexW2167829064

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.